Bagsværd, Denmark, 31 August 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initi

Novo Nordisk stock is steady as the company launches a new phase 3 obesity trial for Asian patients

Novo Nordisk is leaning into convenience as it tries to regain its lead in the GLP-1 weight-loss space.

Novo Nordisk is leaning into convenience as it tries to regain its lead in the GLP-1 weight-loss space.

Novo Nordisk stock is trading against a split analyst backdrop, with shares quoted at DKK 298.10 on

Novo Nordisk stock is trading below its recent highs as a downgrade and China growth worries collide

Con la aprobación, Mounjaro de Eli Lilly se convierte en el primer agonista dual del receptor GIP/GLP-1 indicado para reducir el riesgo de ataque cardíaco, accidente cerebrovascular o muerte cardiovascular en adultos con diabetes tipo 2.

Novo Nordisk stock is under pressure after a downgrade and China filing, even as new phase 3 trials

Novo Nordisk starts Korea phase 3 for dual-action obesity drug CagriSema Phase 3 in Korea tests dual GLP-1 and amylin therapy over 80 weeks with broad hospital participation

Novo Nordisk stock has given investors a difficult few years, with the share price down about 47.0% over the past three years, yet the broader valuation checks currently lean cheap rather than expensive. That contrast is drawing attention to whether the recent weakness has already reset expectations enough for long term holders. The roughly 47.0% share price decline over three years suggests sentiment has cooled sharply compared with earlier enthusiasm. The ongoing focus on GLP-1 obesity...

CNBC’s “Fast Money” team discusses Deutsche's call to downgrade Novo Nordisk to sell from hold, citing a slew of negative catalysts for the rating change.